Cargando…

Lipidomics of Bioactive Lipids in Alzheimer’s and Parkinson’s Diseases: Where Are We?

Lipids are not only constituents of cellular membranes, but they are also key signaling mediators, thus acting as “bioactive lipids”. Among the prominent roles exerted by bioactive lipids are immune regulation, inflammation, and maintenance of homeostasis. Accumulated evidence indicates the existenc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chiurchiù, Valerio, Tiberi, Marta, Matteocci, Alessandro, Fazio, Federico, Siffeti, Hasibullah, Saracini, Stefano, Mercuri, Nicola Biagio, Sancesario, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181703/ https://www.ncbi.nlm.nih.gov/pubmed/35682914 http://dx.doi.org/10.3390/ijms23116235

Ejemplares similares

Macrophage Plasticity and Polarization Are Altered in the Experimental Model of Multiple Sclerosis
por: Leuti, Alessandro, et al.
Publicado: (2021)

Specialized Pro-resolving Lipid Mediators and Glial Cells: Emerging Candidates for Brain Homeostasis and Repair
por: Tiberi, Marta, et al.
Publicado: (2021)

Bioactive Glasses: Where Are We and Where Are We Going?
por: Baino, Francesco, et al.
Publicado: (2018)

Bioactive Lipids and Chronic Inflammation: Managing the Fire Within
por: Chiurchiù, Valerio, et al.
Publicado: (2018)

Alzheimer’s disease and infections, where we stand and where we go
por: Monastero, Roberto, et al.
Publicado: (2014)

Biomarkers for Alzheimer’s Disease: Where Do We Stand and Where Are We Going?
por: Villa, Chiara
Publicado: (2020)

Lipidomics of Bioactive Lipids in Acute Coronary Syndromes
por: Solati, Zahra, et al.
Publicado: (2019)

Venoms as an adjunctive therapy for Parkinson’s disease: where are we now and where are we going?
por: Gazerani, Parisa
Publicado: (2020)

Endogenous versus exogenous cell replacement for Parkinson’s disease: where are we at and where are we going?
por: Mourtzi, Theodora, et al.
Publicado: (2022)

Subtyping of Parkinson’s Disease - Where Are We Up To?
por: Qian, Elizabeth, et al.
Publicado: (2019)

Tuberculosis elimination: where are we now?
por: Matteelli, Alberto, et al.
Publicado: (2018)

Effects of head trauma and sport participation in young-onset Parkinson’s disease
por: Schirinzi, Tommaso, et al.
Publicado: (2021)

Bioactive Compounds for Customized Brain Health: What Are We and Where Should We Be Heading?
por: Begdache, Lina, et al.
Publicado: (2023)

When Cognitive Decline and Depression Coexist in the Elderly: CSF Biomarkers Analysis Can Differentiate Alzheimer's Disease from Late-Life Depression
por: Liguori, Claudio, et al.
Publicado: (2018)

Lipids in Neurodegenerative Diseases
por: Chiurchiù, Valerio
Publicado: (2023)

A PUBLIC HEALTH APPROACH TO ALZHEIMER’S DISEASE RISK REDUCTION: WHERE WE ARE AND WHERE WE’RE HEADED
por: Omura, John, et al.
Publicado: (2022)

Lipidomics to Assess Omega 3 Bioactivity
por: Visioli, Francesco
Publicado: (2015)

New therapies for spinal muscular atrophy: where we stand and what is next
por: Antonaci, Laura, et al.
Publicado: (2023)

Diagnostic biomarkers for Parkinson’s disease at a glance: where are we?
por: Cova, Ilaria, et al.
Publicado: (2018)

Gene and Cell-Based Therapies for Parkinson’s Disease: Where Are We?
por: Buttery, Philip C., et al.
Publicado: (2020)

Designing Socially Assistive Robots for Alzheimer’s Disease and Related Dementia Patients and Their Caregivers: Where We Are and Where We Are Headed
por: Koutentakis, Dimitrios, et al.
Publicado: (2020)

Sleep Dysregulation Is Associated with (18)F-FDG PET and Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease
por: Fernandes, Mariana, et al.
Publicado: (2023)

Where are we now and where are we headed?
por: Langan, Ewan A.
Publicado: (2023)

Tau and Amyloid-β Peptides in Serum of Patients With Parkinson's Disease: Correlations With CSF Levels and Clinical Parameters
por: Schirinzi, Tommaso, et al.
Publicado: (2022)

Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinson’s disease
por: Krashia, Paraskevi, et al.
Publicado: (2019)

Vesicoureteral Reflux: Where Have We Been, Where Are We Now, and Where Are We Going?
por: McLorie, Gordon A.
Publicado: (2008)

TSACO’s Third Anniversary: where we were, where we are, and where we’re going
por: Fabian, Timothy
Publicado: (2019)

The Clusmy Child: Where Are We and Where Are We Going?
por: Hadders-Algra, Mijna, et al.
Publicado: (2003)

European HEPnet: where we are and where we are going
por: Carpenter, B E, et al.
Publicado: (1990)

Iron health: where are we and where are we going?
por: Gotardo, Glória Ines Beal
Publicado: (2011)

Animal Sentience: Where are We and Where are We Heading?
por: Proctor, Helen
Publicado: (2012)

Hip Arthroscopy: Where We Are, and Where We Are Going
por: Park, Myung Sik, et al.
Publicado: (2015)

Diabetic cardiomyopathy: where we are and where we are going
por: Lee, Wang-Soo, et al.
Publicado: (2017)

Obstetric ultrasound: where are we and where are we going?
por: Abramowicz, Jacques S
Publicado: (2021)

Hidradenitis Suppurativa: Where We Are and Where We Are Going
por: Scala, Emanuele, et al.
Publicado: (2021)

COVID-19: Where We Are, Where We Need to Be
por: Bender Ignacio, Rachel A., et al.
Publicado: (2022)

Where We Are and Where We Are Going in Nut Research
por: Salas-Salvadó, Jordi, et al.
Publicado: (2023)

COVID-19: Where We Are and Where We Are Going
por: Abenavoli, Ludovico, et al.
Publicado: (2023)

Telemedicine in ophthalmology - where are we and where are we going?
por: Pîrvulescu, Ruxandra
Publicado: (2023)

Research Integrity: Where We Are and Where We Are Heading
por: Zhaksylyk, Alikhan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vc7hrcgqp965i85sd4ds4gnq80